Systemic Therapy for Metastatic Non-Clear Cell Renal Carcinoma

Parham Khosravi-Shahi*

*Head of Medical Oncology Department, Hospital Universitario de Torrejón, Spain

Submission: March 29, 2016; Published: April 07, 2017

*Correspondence Address: Parham Khosravi-Shahi, Head of Medical Oncology Department, Hospital Universitario de Torrejón, Servicio de Oncología, Calle Mateo Inurria, s/n, Torrejón de Ardoz, Spain, Email: drkhosravi@hotmail.com

Abstract

Renal cell carcinoma (RCC) comprises 2-3% of all malignancies. Approximately 90% of renal tumors are RCCs, and 15% of these are non-clear cell tumors, which include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors. Antiangiogenic agents (sorafenib, sunitinib, pazopanib, temsirolimus, or bevacizumab), have not been specifically evaluated in phase III trials in patients with non-clear cell tumors. Therefore, their efficacy is unclear in the treatment of non-clear cell renal carcinomas. In a subset analysis of a randomized phase III trial, patients with non-clear cell and clear cell advanced RCCs, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. In addition, temsirolimus resulted in a superior clinical benefit rate compared with interferon-alfa, regardless of tumor histology. Patients with metastatic papillary and chromophobe RCCs may have prolonged progression-free survival from sunitinib and sorafenib, although clinical responses remain overall low. Therefore, although there are some evidences supporting the use of these agents in patients with non-clear cell RCCs, additional prospective trials with these agents are needed to further clarify their use in these histologic subtypes. This review article focuses on all these options for non-clear cell advanced RCC.

Introduction

Renal cell carcinoma (RCC) accounts for 2-3% of all malignant diseases in adults. It is the seventh most common cancer in men and the ninth most common in women [1]. Incidence worldwide is about 209,000 new cases per year and 102,000 deaths per year. The incidence of all stages of this cancer has increased over several years, contributing to a steadily increasing mortality rate per unit population [2,3]. RCC is a male predominant (2:1 ratio) disease with a typical presentation in the sixth and seventh decades of life (median age about 60 years). Patients with this cancer can present with local or systemic symptoms, although most presentations are incidental with the widespread use of abdominal imaging. Local signs and symptoms include haematuria, flank pain, or a palpable abdominal mass. Systemic symptoms can be due to metastases or paraneoplastic events [4].

Figure 1: Non-clear cell renal cell carcinomas (RCC). 1A. Papillary RCC: the tumor cells lining papillary fronds have moderate amounts of eosinophilic cytoplasm and uniform round or oval nuclei with little atypical; 1B. Collecting Duct RCC: the tumor cells are arranged in duct-like structures, irregular nests or infiltrate singly. Hobnail appearance, seen clearly in this duct, is a helpful diagnostic feature; 1C. Chromophobe RCC: Microscopically, it is composed of variably-sized cells with abundant pale reticular or flocculent cytoplasm. The nuclei are moderately sized and hyper chromatic. Bi- and multinucleated cells are not uncommon. 1D. Sarcomatoid RCC: Approximately 5% of RCC cases show sarcomatoid change. The sarcomatoid areas generally show features of fibrosarcoma, or undifferentiated spindle cell sarcoma.
RCC, which accounts for 90% of renal tumors, is not a homogenous entity. A number of malignant histologic subtypes of RCC are recognized by the Heidelberg classification system [5], and clear cell carcinoma is the most common histologic subtype (85%). Approximately 15% of the remaining RCCs are non-clear cell tumors, and include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors (Figure 1). Papillary and chromophobe RCCs represent the most common non-clear cell histologic subtypes with an incidence of 7% to 15% and 6% to 11%, respectively [6]. Each RCC subtype is associated with unique genetic alterations, clinical characteristics, and sensitivity to treatment [7].

Recent advances in understanding the biology and genetics of RCC have led to major therapeutic implications. The role of the von Hippel-Lindau (VHL) gene in regulating proangiogenic factors has provided potential targets for novel agents. VHL gene inactivation, present in the majority of sporadic forms of RCC, leads to a defective VHL protein, followed by an active transcription of hypoxia-inducible genes, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. Many of these gene products are involved in angiogenesis, tumor progression, and survival. However, the concept of VHL inactivation in RCC and the subsequent malignant phenotype is almost exclusively seen in patients with clear cell histology [8,9].

Trials with small-molecule VEGF and PDGF receptor inhibitors, such as sunitinib, sorafenib and pazopanib have shown significant clinical activity in randomized trials in clear cell advanced RCC and have largely replaced cytokines as standard of care in this disease [10,11]. Earlier studies with cytokines agents showed minimal activity in patients with non-clear cell advanced RCC. These studies were mostly based on small series and case reports. Moreover, less than 10% of patients with non-clear cell histology were included on clinical trials of new investigational agents, such as sunitinib, pazopanib and sorafenib. However, there are more data about the efficacy of temsirolimus in the treatment of non-clear cell advanced RCC [12]. On the other hand, some cytotoxic agents, such as gemcitabine and doxorubicin, have shown a moderate activity in sarcomatoid RCC.

Non-Clear Cell Renal Cell Carcinomas

Papillary RCC is the second most common histologic subtype of the kidney cancer accounting for approximately 7% to 15% of cases, and nearly 29% of all RCCs in African Americans. It can be further categorized histologically into papillary types I and II [13]. Papillary type I RCC is associated with activating mutations of the methyl-nitro so-nitroguanidine-induced (MET) oncogene on the long arm of chromosome 7 [14]. These mutations result in ligand-independent activation of intracytoplasmic tyrosine kinase (TK) domains, which constitutively activate the hepatocytes growth factor/ MET pathway [15]. Papillary type II tumors occur both sporadically and in patients who have the familial syndrome of hereditary leiomyomatosis and renal cell carcinoma [16]. The genetic alteration associated with this syndrome has been localized to chromosome 1 and the gene identified as fumarate hydratase, which functions as a tumor suppressor, with both copies inactivated in tumors [17]. These tumors have characteristic large oncoplastic nuclei and a clear perinuclear halo, with a variety of architectural patterns such as papillary, tubulo-papillary, tubular, solid or mixed [18].

Chromophobe RCC accounts for approximately 6% to 11% of all RCCs, and is often detected while still confined to the kidney, as fewer than 5% of cases are metastatic at the time of diagnosis [19]. The mechanisms underlying the genesis of this subtype of RCC are not well understood. However, Birt-Hogg-Dubé (BHD) is an autosomal dominant hereditary cancer syndrome associated with bilateral, multifocal chromophobe RCC [20]. The BHD gene, FLCN, located on the short arm of chromosome 17, was identified by genetic linkage analysis, and is altered via insertion, deletion or nonsense mutations in the germline of the vast majority of affected individuals. The protein product of BHD, folliculin, functions as a tumor suppressor [21,22].

Collecting duct RCC is extremely rare, accounting for less than 1% of all RCCs, and is associated with a grave prognosis, with approximately one-third of patients having metastases at the time of diagnosis. Sarcomatoid RCC is another rare histologic subtype of RCC, and is associated with poor prognosis. The median time to progression for advanced sarcomatoid renal tumors is approximately 2 months and median overall survival (OS) is 4 to 7 months [23].

Efficacy of Multi-Kinase Inhibitors as First Line Therapy: Sunitinib, Sorafenib and Pazopanib

Sunitinib is an orally administered inhibitor of multiple TKs, including VEGFR -1, -2, -3, PDGFR (-cand-β stem cell factor receptor (c-KIT), colony stimulating factor (CSF-1R) and neurotrophic factor receptor (RET) [24]. In a phase III trial, the efficacy of sunitinib in first line therapy was demonstrated in favorable-intermediate risk groups with predominantly clear cell advanced RCC. Sorafenib is another small molecule that inhibits multiple is forms of the intracellular serine/threonine kinase, RAF, and also other receptor TKs, including VEGFR-1, -2, -3, PDGFR-β, FLT-3, c-KIT and RET [25,26].

A randomized phase II trial investigated the efficacy and safety of sorafenib versus interferon-alpha-2a in previously untreated patients with predominantly clear cell advanced RCC [27]. In this study, sorafenib resulted in similar progression free survival (PFS) as interferon-alpha-2a in patients with untreated RCC (median PFS of 5.7 vs 5.6 months, respectively). However, sorafenib-treated patients experienced greater rates of tumor size reduction, better quality of life, and improved
and chromophobe RCCs may have prolonged PFS from sunitinib (PFS of 11.9 months compared with 5.1 months for sorafenib-with sunitinib). Sunitinib-treated papillary RCC patients had a response (both patients were treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 papillary RCC patients achieved a response (both patients were treated with sunitinib), and PFS was 10.6 months. The ORR, PFS, and OS for the entire study population (median PFS, 9.2 vs 4.2 months; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < 0.0001), the treatment-naïve subpopulation (median PFS, 11.1 vs 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60; P < 0.0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 vs 4.2 months; HR, 0.54; 95% CI, 0.35 to 0.84; P < 0.001). The overall response rate (ORR) was 30% with pazopanib compared with 3% with placebo (P < 0.001) [28].

However, less than 10% of patients with non-clear cell histology’s were included on clinical trials of new investigational agents, such as sunitinib, pazopanib and sorafenib. Therefore, their efficacy in non-clear cell RCCs is unclear. Recent data revealed that sunitinib and sorafenib is safe and may be efficacious in patients with non-clear cell tumors. In an expanded access trial, sunitinib was effective in the subgroup of patients with non-clear cell histology, as well as, patients with treated brain metastases and poor performance status (PS). In this study, 4,564 patients were enrolled in 52 countries, and 4,371 patients were included in the modified intention-to-treat population. This population included 588 patients (13%) with non-clear cell RCCs. The ORR was 11% for non-clear cell RCCs. The median PFS was 10.9 months and median OS was 18.4 months. The most common grade 3-4 adverse events were fatigue (8%) and thrombocytopenia (8%), with incidences of grade 3-4 adverse events similar across subgroups [29].

In another study conducted by Choueiri et al. [30], the efficacy and safety of sunitinib and sorafenib was evaluated in patients with metastatic papillary and chromophobe RCCs. In this study, 53 patients were included, and the number of patients with papillary and chromophobe histologies was 41 (77%) and 12 (23%), respectively. The ORR, PFS, and OS for the entire cohort were 10%, 8.6 months, and 19.6 months, respectively. Twenty-five percent of chromophobe RCCs achieved a response (two patients treated with sunitinib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 papillary RCC patients achieved a response (both patients were treated with sunitinib). Sunitinib-treated papillary RCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). In conclusion, patients with papillary and chromophobe RCCs may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in papillary RCC. On the other hand, the efficacy of pazopanib has not yet been studied in patients with non-clear cell RCCs. In summary, although there are some evidences supporting the use of these agents in patients with non-clear cell RCCs, additional prospective trials with these agents are needed to further clarify their use in these histologic subtypes.

Temsirilimus as First Line Therapy

Temsirilimus is an inhibitor of the mammalian Target of Rapamycin (mTOR) protein, which regulates microtubulins, cell growth, apoptosis and angiogenesis by its downstream effects on a variety of proteins. Efficacy and safety of temsirilimus was demonstrated in a multicenter, randomized, open-label phase III trial (Global Advanced Renal Cell Carcinoma [ARCC] trial) in previously untreated patients with advanced RCC who had at least 3 unfavorable prognostic factors [31]. In this trial, 626 patients were randomly assigned to receive 25 mg of intravenous temsirilimus weekly, 3 million U of interferon-alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirilimus weekly plus 6 million U of interferon-alfa three times weekly. As compared with interferon-alfa, patients who received temsirilimus alone had longer OS (HR, 0.73; P=0.008) and PFS (P<0.001) in the entire population. In the combination-therapy group OS did not differ significantly from that in the interferon group (HR, 0.96; P=0.70). Median OS in the interferon group, the temsirilimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively.

Temsirilimus is the only agent that has shown activity in patients with non-clear cell RCCs in a subset analysis of ARCC trial [32]. Approximately 18% of patients had non-clear cell carcinoma, the majority of which were papillary. The baseline characteristics of patients with non-clear cell or clear cell histologies in the interferon and temsirilimus groups were generally balanced and similar to those of all patients in the study. Thirty-six (17%) patients in the interferon group and 37 (18%) patients in the temsirilimus group had non-clear cell RCCs. Patients with non-clear cell and clear cell advanced RCCs, treated with temsirilimus, had comparable median PFS (7.0 vs 5.5 months, respectively) and OS (11.6 vs 10.7 months, respectively). In contrast, patients with non-clear cell histology’s were treated with interferon demonstrated a shorter median OS than patients with tumors of clear cell histology (4.3 vs 82 months, respectively). As compared with interferon-alfa, patients with non-clear cell RCCs who received temsirilimus had longer PFS (median 1.8 vs 7.0 months; HR, 0.38, 95% confidence interval [CI]: 0.23-0.62) and OS (median 4.3 vs 11.6 months; HR, 0.49, 95% CI: 0.29-0.85; Table 1). In addition, temsirilimus resulted in a superior clinical benefit rate compared with interferon-alfa, regardless of tumor histology. Therefore, temsirilimus is a category 1 recommendation for first-line treatment in patients with non-clear cell advanced RCCs with poor prognosis features.
Table 1: Overall and progression-free survival in patients with advanced renal cell carcinoma treated with interferon-alpha and temsirolimus in ARCC trial.

<table>
<thead>
<tr>
<th>Primary cell type</th>
<th>Median PFS (months)</th>
<th>Hazard Ratio (95% CI)</th>
<th>Median OS (months)</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IFN</td>
<td>Tem</td>
<td></td>
<td>IF</td>
</tr>
<tr>
<td>Non-clear cell</td>
<td>1.8</td>
<td>7.0</td>
<td>0.38 (0.23-0.62)</td>
<td>4.3</td>
</tr>
<tr>
<td>Clear cell</td>
<td>3.7</td>
<td>5.5</td>
<td>0.76 (0.60-0.97)</td>
<td>8.2</td>
</tr>
</tbody>
</table>

PFS: Progression-Free Survival; OS: Overall Survival; IFN: Interferon; Tem: Temsirolimus; CI: Confidence Interval.

Chemotherapy and Erlotinib

Chemotherapy is another therapeutic option for patients with non-clear cell advanced RCCs, especially for sarcomatoid collecting duct histologies. Sarcomatoid RCCs are rare and aggressive tumors associated with poor outcome, and there is no standard therapy for them. Immunotherapy and antiangiogenic therapies are generally ineffective in sarcomatoid RCCs. However, different cytotoxic agents, such as gemcitabine and doxorubicin, have a modest antitumor activity in these tumors. In a study conducted by Nanus, et al. [33], gemcitabine in combination with doxorubicin was evaluated in patients with sarcomatoid RCCs. In this study, 18 patients with advanced RCC (56% with sarcomatoid tumors and 44% with other histologies) were treated with a regimen consisting of doxorubicin 50 mg/m2 and gemcitabine 1,500-2,000 mg/m2, administered every two weeks with growth factor support. Two patients had a complete response (CR), five had a partial response (PR), and two patients had stable disease of more than 6 months of duration, and the median duration of response was 5 months (range, 2-21 months). This therapy was generally well tolerated with no grade 4 toxicities. Among the 18 patients, four were long-term survivors [34].

Collecting duct RCCs account for less than 1% of all RCCs, and is associated with a grave prognosis. Due to the rarity of this disease, there is scant evidence to guide treatment recommendations, and no randomized clinical trials have been completed. In a phase II trial, 23 patients with collecting duct advanced RCCs were treated with gemcitabine plus cisplatin or carboplatin, depending on renal function. This regimen was selected based on the histologic similarities between collecting duct RCC and transitional cell carcinoma of the urinary bladder. The ORR was 26% (5 PR and 1 CR) as measured by an independent radiologic review. The median PFS of the study was 7.1 months, and the median OS was 10.5 months [35]. Based on this study, gemcitabine plus cisplatin is the most recommended treatment for collecting duct advanced RCCs.

Another TK inhibitor, erlotinib, has also been evaluated in the treatment of non-clear cell advanced RCCs. Erlotinib is an oral epidermal growth factor receptor TK inhibitor. In a multicenter phase II trial, 52 patients with locally advanced and metastatic papillary RCCs were treated with this agent. The ORR of this study was 11%, and the disease control rate was 64%. The 6-month PFS was only 29%; however, the median OS was 27 months. There was one grade 5 adverse event (AE) of pneumonitis, one grade 4 thromboses, and nine other grades 3 AEs [36]. Despite of these interesting results, there is no enough evidence to recommend the use of erlotinib in the treatment of non-clear cell RCCs.

Conclusion

Non-clear cell RCCs account for 15% of all RCCs, and each histologic subtype is associated with unique genetic alterations, clinical characteristics, and sensitivity to treatment. Antiangiogenic agents (sorafenib, sunitinib, pazopanib, everolimus or bevacizumab), have not been tested in phase III trials in patients with non-clear cell tumors. Therefore, their efficacy is unclear in the treatment of non-clear cell RCCs. In a subset analysis of a phase III trial (ARCC trial), patients with non-clear cell and clear cell advanced RCCs with poor prognosis, treated with temsirolimus, demonstrated comparable median PFS and OS.

In addition, temsirolimus resulted in a superior clinical benefit rate compared with interferon-alpha, regardless of tumor histology. Hence, temsirolimus is a category 1 recommendation for first-line treatment in patients with non-clear cell advanced RCCs with poor prognosis features. Patients with metastatic papillary and chromophobe RCCs may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low. Therefore, although there are some evidences supporting the use of these agents in patients with non-clear cell RCCs, additional prospective trials with these agents are needed to further clarify their use in these histologic subtypes. On the other hand, some cytotoxic agents combinations, such as gemcitabine plus doxorubicin or gemcitabine plus cisplatin, have shown a moderate activity in sarcomatoid and collecting duct advanced RCCs, respectively.

Reference


